Skip to main content

Pilot & Feasibility

DRC P&F 2024 Grant Announcement

2024 Pilot and Feasibility Projects in Endocrinology & Diabetes

Pilot & Feasibility Program Director: Peter Tontonoz

As part of the mission of our UCSD/UCLA Diabetes Research Center (DRC) grant, the Pilot and Feasibility grant program will support grantees at approximately $40,000-50,000 direct costs (with additional ~55% indirect costs) in 2024. The maximum number of P&F awards an investigator may receive is two. Successful applicants can apply to have their first year of funding renewed for a second year by re-applying the following year, or may submit a second application in a subsequent year.

Applications Due: Friday, March 15, 2024 to Dr. Peter Tontonoz at ptontonoz@mednet.ucla.edu

The DRC P&F mechanism will fund innovative new projects that will explore the feasibility of novel testable concepts and enhance the endocrine/diabetes research scope within the institutions. A special emphasis on promoting promising junior faculty involved with diabetes research is key to the UCSD/UCLA P&F mission. It is expected that P&F studies will generate preliminary data that will be used by these investigators in diabetes/endocrinology-related R01 applications in the years following their award.

Application Process

Eligible investigators must have faculty appointments at UCLA, Salk, Cedars, or UCSD, and be independent investigators. The DRC is also pleased to partner with the CTSIs at UCLA, Cedars and UCSD to specifically support clinical and/or translational research relevant to diabetes. The DRC strongly encourages submission of pilot and feasibility proposals in this area. Be sure to follow the formatting requirements for the administrative qualification for the proposal. 

How to Apply

All papers must cite P30 DK063491 and obtain a PMCID number from NCBI. 
Please cite the DRC Grant in all papers that utilize DRC Cores or are supported by the Pilot and Feasibility Awards:

"Our research utilized Core (or Research) support from the UCSD/UCLA NIDDK Diabetes Research Center P30 DK063491."